Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidekazu Shirota

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
Urologia Internationalis|July 13, 2025
Course of Multimodal Therapy and Genetic Profile of Hereditary Leiomyomatosis and Renal Cell Carcinoma with Early Recurrence during Adjuvant Therapy after Radical Nephrectomy: A Case ReportHiroshi Masuda, Tomonori Sato, Satoko Sato, et al.
The Tohoku Journal of Experimental Medicine|May 21, 2019
Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series StudyKen Saijo, Hiroo Imai, Kota Ouchi, et al.
Frontiers in Oncology|February 16, 2026
Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic <i>TSC2</i> mutationsShiori Ishikawa, Kota Ouchi, Shonosuke Wakayama, et al.
International Cancer Conference Journal|June 1, 2019
Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugsShunsuke Sugiyama, Mariko Ishizuka, Masanobu Takahashi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 26, 2022
[Panel Discussion - Problems in the Cancer Genomic Medicine]Chikashi Ishioka, Manabu Muto, Shinichi Yachida, et al.
Cancer Science|October 6, 2025
Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case ReportMaako Kawamura, Hiroshi Tada, Hidekazu Shirota, et al.
Frontiers in Oncology|September 4, 2023
Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimensKen Saijo, Hiroo Imai, Kota Ouchi, et al.
Journal of Oncology|July 14, 2020
Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer PatientsHiroo Imai, Ken Saijo, Keigo Komine, et al.
Oncology|October 30, 2023
Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective StudyHiroo Imai, Ken Saijo, Yoshifumi Kawamura, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
Chylous Ascites Associated with Advanced Pancreatic Cancer That Improved with Appropriate Treatment: A Case ReportHiroo Imai, Ken Saijo, Noriko Takenaga, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Urologia Internationalis|July 13, 2025
Course of Multimodal Therapy and Genetic Profile of Hereditary Leiomyomatosis and Renal Cell Carcinoma with Early Recurrence during Adjuvant Therapy after Radical Nephrectomy: A Case ReportHiroshi Masuda, Tomonori Sato, Satoko Sato, et al.
The Tohoku Journal of Experimental Medicine|May 21, 2019
Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series StudyKen Saijo, Hiroo Imai, Kota Ouchi, et al.
Frontiers in Oncology|February 16, 2026
Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic <i>TSC2</i> mutationsShiori Ishikawa, Kota Ouchi, Shonosuke Wakayama, et al.
International Cancer Conference Journal|June 1, 2019
Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugsShunsuke Sugiyama, Mariko Ishizuka, Masanobu Takahashi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 26, 2022
[Panel Discussion - Problems in the Cancer Genomic Medicine]Chikashi Ishioka, Manabu Muto, Shinichi Yachida, et al.
Cancer Science|October 6, 2025
Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case ReportMaako Kawamura, Hiroshi Tada, Hidekazu Shirota, et al.
Frontiers in Oncology|September 4, 2023
Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimensKen Saijo, Hiroo Imai, Kota Ouchi, et al.
Journal of Oncology|July 14, 2020
Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer PatientsHiroo Imai, Ken Saijo, Keigo Komine, et al.
Oncology|October 30, 2023
Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective StudyHiroo Imai, Ken Saijo, Yoshifumi Kawamura, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
Chylous Ascites Associated with Advanced Pancreatic Cancer That Improved with Appropriate Treatment: A Case ReportHiroo Imai, Ken Saijo, Noriko Takenaga, et al.
Pageof 9